Functional/JJ
Prediction/NN
of/IN
Hypothetical/JJ
Proteins/NNS
from/IN
Shigella/NN
flexneri/NN
and/CC
Validation/NN
of/IN
the/DT
Predicted/JJ
Models/NNS
by/IN
Using/VBG
ROC/NN
Curve/NN
Analysis/NN
./.
====================
Shigella/NN
spp/NN
./.
====================
constitutes/VBZ
some/DT
of/IN
the/DT
key/JJ
pathogens/NNS
responsible/JJ
for/IN
the/DT
global/JJ
burden/NN
of/IN
diarrhoeal/JJ
disease/NN
./.
====================
With/IN
over/IN
164/CD
million/NN
reported/VBD
cases/NNS
per/FW
annum/FW
,/,
shigellosis/NN
accounts/NNS
for/IN
1.1/CD
million/NN
deaths/NNS
each/DT
year/NN
./.
====================
Majority/NN
of/IN
these/DT
cases/NNS
occur/VBP
among/IN
the/DT
children/NN
of/IN
the/DT
developing/VBG
nations/NNS
and/CC
the/DT
emergence/NN
of/IN
multi-drug/JJ
resistance/NN
Shigella/NN
strains/NNS
in/IN
clinical/JJ
isolates/NNS
demands/VBZ
the/DT
development/NN
of/IN
better/new/JJ
drugs/NNS
against/IN
this/DT
pathogen/NN
./.
====================
The/DT
genome/NN
of/IN
Shigella/NN
flexneri/NN
was/VBD
extensively/RB
analyzed/VBD
and/CC
found/VBD
4,362/CD
proteins/NNS
among/IN
which/WDT
the/DT
functions/NNS
of/IN
674/CD
proteins/NNS
,/,
termed/VBN
as/IN
hypothetical/JJ
proteins/NNS
(/(
HPs/NNS
)/)
had/VBD
not/RB
been/VBN
previously/RB
elucidated/VBN
./.
====================
Amino/DT
acid/NN
sequences/NNS
of/IN
all/DT
these/DT
674/CD
HPs/NNS
were/VBD
studied/VBN
and/CC
the/DT
functions/NNS
of/IN
a/DT
total/JJ
of/IN
39/CD
HPs/NNS
have/VBP
been/VBN
assigned/VBN
with/IN
high/JJ
level/NN
of/IN
confidence/NN
./.
====================
Here/RB
we/PRP
have/VBP
utilized/VBN
a/DT
combination/NN
of/IN
the/DT
latest/JJ
versions/NNS
of/IN
databases/NNS
to/TO
assign/VB
the/DT
precise/JJ
function/NN
of/IN
HPs/NNS
for/IN
which/WDT
no/DT
experimental/JJ
information/NN
is/VBZ
available/JJ
./.
====================
These/DT
HPs/NNS
were/VBD
found/VBN
to/TO
belong/VB
to/TO
various/JJ
classes/NNS
of/IN
proteins/NNS
such/JJ
as/IN
enzymes/NNS
,/,
binding/VBG
proteins/NNS
,/,
signal/NN
transducers/NNS
,/,
lipoprotein/NN
,/,
transporters/VBZ
,/,
virulence/NN
and/CC
other/JJ
proteins/NNS
./.
====================
Evaluation/NN
of/IN
the/DT
performance/NN
of/IN
the/DT
various/JJ
computational/JJ
tools/NNS
conducted/VBN
using/VBG
receiver/RB
operating/VBG
characteristic/JJ
curve/JJ
analysis/NN
and/CC
a/DT
resoundingly/RB
high/JJ
average/NN
accuracy/NN
of/IN
93.6/CD
%/NN
were/VBD
obtained/VBN
./.
====================
Our/PRP$
comprehensive/JJ
analysis/NN
will/MD
help/VB
to/TO
gain/VB
greater/JJR
understanding/NN
for/IN
the/DT
development/NN
of/IN
many/JJ
novel/JJ
potential/JJ
therapeutic/JJ
interventions/NNS
to/TO
defeat/VB
Shigella/NN
infection/NN
./.
====================
Shigella/NN
,/,
refers/VBZ
to/TO
a/DT
genus/JJ
of/IN
gram-negative/JJ
facultative/JJ
anaerobes/NNS
that/DT
belongs/VBZ
to/TO
members/NNS
of/IN
the/DT
family/NN
Enterobacteriaceae/NN
and/CC
is/VBZ
the/DT
causative/JJ
agent/NN
of/IN
shigellosis/NN
,/,
a/DT
severe/JJ
enteric/JJ
infection/NN
,/,
one/CD
of/IN
the/DT
most/JJS
common/JJ
causes/VBZ
of/IN
morbidity/NN
and/CC
mortality/NN
among/IN
children/NN
in/IN
developing/VBG
nations/NNS
./.
====================
The/DT
Global/JJ
Burden/NN
of/IN
Disease/NN
(/(
GBD/NN
)/)
classified/VBD
Shigella/NN
as/IN
the/DT
second/JJ
leading/VBG
cause/VBP
of/IN
diarrheal/JJ
deaths/NNS
on/IN
a/DT
global/JJ
scale/NN
in/IN
2015/CD
[/(
1/CD
]/)
./.
====================
Shigellosis/NN
leads/VBZ
to/TO
the/DT
recurrent/JJ
passing/VBG
of/IN
small/JJ
,/,
bloody/NN
mucoidal/JJ
stools/NNS
with/IN
synchronous/JJ
abdominal/JJ
cramps/NNS
and/CC
tenesmus/NN
caused/VBD
by/IN
ulceration/NN
of/IN
the/DT
colonic/JJ
epithelium/NN
[/(
2/CD
]/)
./.
====================
In/IN
malnourished/JJ
children/NN
,/,
Shigella/NN
infection/NN
may/MD
lead/VB
to/TO
a/DT
vicious/JJ
cycle/NN
of/IN
further/JJ
impaired/JJ
nutrition/NN
,/,
frequent/JJ
infection/NN
and/CC
growth/NN
retardation/NN
resulting/VBG
from/IN
protein/NN
loss/NN
enteropathy/JJ
[/(
3/CD
]/)
./.
====================
The/DT
Shigella/NN
genus/NN
is/VBZ
divided/VBN
into/IN
four/CD
species/NNS
:/:
Shigella/NN
flexneri/NN
,/,
Shigella/NN
boydii/NN
,/,
Shigella/NN
sonnei/NNS
,/,
and/CC
Shigella/NN
dysenteriae/NN
./.
====================
These/DT
are/VBP
further/RBR
classified/VBN
into/IN
serotypes/NNS
based/VBN
on/IN
biochemical/JJ
differences/NNS
and/CC
variations/NNS
in/IN
their/PRP$
O-antigen/NN
[/(
4/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
19/CD
different/JJ
serotypes/NNS
of/IN
S./NNP
flexneri/NN
have/VBP
been/VBN
reported/VBN
so/RB
far/RB
by/IN
various/JJ
research/NN
groups/NNS
[/(
5/CD
]/)
./.
====================
Among/IN
the/DT
four/CD
Shigella/NN
species/NNS
,/,
shigellosis/NN
is/VBZ
predominantly/RB
caused/VBD
by/IN
S./NNP
flexneri/NN
in/IN
the/DT
developing/VBG
world/NN
especially/RB
in/IN
Asia/NN
,/,
and/CC
is/VBZ
responsible/JJ
for/IN
approximately/RB
10/CD
%/NN
of/IN
all/DT
diarrheal/JJ
episodes/NNS
among/IN
children/NN
of/IN
</JJR
5/CD
years/NNS
[/(
6/CD
]/)
./.
====================
Recent/JJ
multicenter/JJ
study/NN
in/IN
Asia/NN
revealed/VBD
that/IN
the/DT
incidence/NN
of/IN
this/DT
disease/NN
might/MD
even/RB
exceed/RB
previous/JJ
estimations/NNS
,/,
due/JJ
to/TO
Shigella/NN
DNA/NN
being/VBG
detectable/JJ
in/IN
up/IN
to/TO
one/CD
third/JJ
of/IN
the/DT
total/JJ
culture/NN
negative/JJ
specimens/NNS
[/(
7/CD
]/)
./.
====================
Currently/RB
,/,
no/DT
effective/JJ
vaccine/NN
with/IN
the/DT
ability/NN
to/TO
confer/VB
adequate/NN
protection/NN
against/IN
the/DT
many/JJ
different/JJ
serotypes/NNS
of/IN
Shigella/NN
has/VBZ
been/VBN
developed/VBN
and/CC
made/VBD
available/JJ
./.
====================
Existing/VBG
antimicrobial/JJ
treatments/NNS
are/VBP
becoming/VBG
compromised/VBN
in/IN
terms/NNS
of/IN
efficacy/NN
due/JJ
to/TO
increased/VBN
antibiotic/JJ
resistance/NN
,/,
soaring/VBG
cost/JJ
of/IN
treatment/NN
,/,
and/CC
persistence/NN
of/IN
poor/JJ
hygiene/NN
and/CC
unsanitary/JJ
conditions/NNS
in/IN
the/DT
developing/VBG
world/NN
./.
====================
A/DT
particular/JJ
study/NN
conducted/VBD
on/IN
numerous/JJ
isolates/NNS
of/IN
Shigella/NN
collected/JJ
over/IN
a/DT
time/NN
span/NN
of/IN
10/CD
years/NNS
,/,
multi-drug/NN
resistance/NN
(/(
MDR/NN
)/)
were/VBD
found/VBN
to/TO
be/VB
exhibited/VBD
by/IN
78.5/CD
%/NN
of/IN
the/DT
isolates/NNS
./.
====================
2/CD
%/NN
of/IN
the/DT
isolates/NNS
were/VBD
found/VBN
to/TO
harbor/VB
genetic/JJ
information/NN
capable/JJ
of/IN
conferring/VBG
resistance/NN
to/TO
azithromycin/NN
,/,
a/DT
final/JJ
resort/NN
antimicrobial/JJ
agent/NN
for/IN
shigellosis/NN
[/(
8/CD
]/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
a/DT
recent/JJ
whole/JJ
genome/NN
analysis/NN
of/IN
a/DT
particular/JJ
strain/NN
of/IN
S./NNP
flexneri/NN
revealed/VBD
82/CD
distinct/JJ
chromosomal/JJ
antibiotic/JJ
resistance/NN
genes/NNS
while/IN
successive/JJ
re-sequencing/VBG
platforms/NNS
elucidated/VBN
several/JJ
distinct/JJ
single/JJ
nucleotide/NN
polymorphisms/NNS
that/DT
contributed/VBD
to/TO
eventual/JJ
MDR/NN
[/(
9/CD
]/)
./.
====================
Therefore/RB
,/,
the/DT
development/NN
of/IN
new/JJ
drugs/NNS
has/VBZ
risen/NN
to/TO
become/VB
a/DT
subject/JJ
of/IN
immense/JJ
magnitude/NN
to/TO
not/RB
only/RB
shorten/RB
the/DT
medication/NN
period/NN
but/CC
also/RB
to/TO
treat/VB
MDR/NN
shigellosis/NN
./.
====================
The/DT
genome/NN
sequence/NN
of/IN
S./NNP
flexneri/NN
serotype/JJ
2a/NN
strain/NN
2457T/CD
,/,
available/JJ
in/IN
the/DT
NCBI/NN
database/NN
consists/VBZ
of/IN
4,599,354/CD
bp/NN
in/IN
a/DT
single/JJ
circular/JJ
chromosome/NN
containing/VBG
4,906/CD
genes/NNS
encoding/VBG
4,362/CD
proteins/NNS
and/CC
has/VBZ
G/NN
+/CC
C/NN
content/JJ
of/IN
50.9/CD
%/NN
[/(
10/CD
]/)
./.
====================
Among/IN
these/DT
,/,
the/DT
functions/NNS
of/IN
674/CD
proteins/NNS
have/VBP
not/RB
been/VBN
experimentally/RB
determined/VBN
till/RB
date/NN
and/CC
are/VBP
termed/VBN
as/IN
hypothetical/JJ
proteins/NNS
(/(
HPs/NNS
)/)
./.
====================
A/DT
HP/NN
is/VBZ
one/CD
that/DT
has/VBZ
been/VBN
predicted/VBN
to/TO
be/VB
encoded/VBN
by/IN
an/DT
identified/VBN
open/JJ
reading/NN
frame/NN
,/,
but/CC
for/IN
which/WDT
there/EX
is/VBZ
a/DT
lack/NN
of/IN
experimental/JJ
evidence/NN
[/(
11/CD
]/)
./.
====================
Nearly/RB
half/NN
of/IN
the/DT
proteins/NNS
in/IN
most/JJS
genomes/NNS
belong/IN
to/TO
the/DT
class/NN
of/IN
HPs/NNS
and/CC
this/DT
class/NN
of/IN
proteins/NNS
presumably/RB
have/VBP
their/PRP$
own/JJ
importance/NN
to/TO
complete/JJ
genomic/JJ
and/CC
proteomic/JJ
platform/NN
of/IN
an/DT
organism/NN
[/(
12/CD
,/,
13/CD
]/)
./.
====================
Precise/JJ
annotation/NN
of/IN
the/DT
HPs/NNS
of/IN
particular/JJ
genome/NN
leads/VBZ
to/TO
the/DT
discovery/NN
of/IN
new/JJ
structures/NNS
as/IN
well/RB
as/IN
new/JJ
functions/NNS
,/,
and/CC
elucidating/VBG
a/DT
list/NN
of/IN
additional/JJ
protein/NN
pathways/NNS
and/CC
cascades/NNS
,/,
thus/RB
completing/VBG
our/PRP$
incomplete/JJ
understanding/VBG
on/IN
the/DT
mosaic/JJ
of/IN
proteins/NNS
[/(
13/CD
]/)
./.
====================
HPs/NNS
may/MD
possibly/RB
play/VB
crucial/JJ
roles/NNS
in/IN
disease/NN
progression/NN
and/CC
survival/NN
of/IN
pathogen/NN
[/(
11/CD
,/,
14/CD
]/)
./.
====================
Furthermore/RB
,/,
novel/JJ
HPs/NNS
may/MD
also/RB
serve/VBP
as/IN
markers/NNS
and/CC
pharmacological/JJ
targets/NNS
for/IN
development/NN
of/IN
new/JJ
drugs/NNS
and/CC
therapies/NNS
[/(
15/CD
]/)
./.
====================
Functions/NNS
of/IN
HPs/NNS
from/IN
several/JJ
pathogenic/JJ
organisms/NNS
have/VBP
been/VBN
already/RB
reported/VBN
using/VBG
a/DT
plethora/NN
of/IN
sequence/NN
and/CC
structure/NN
based/VBN
methods/NNS
[/(
14/CD
,/,
16/CD
,/,
17/CD
]/)
./.
====================
Functional/JJ
annotation/NN
of/IN
HPs/NNS
utilizing/VBG
advanced/JJ
bioinformatics/NNS
tools/NNS
is/VBZ
a/DT
well-established/JJ
platform/NN
in/IN
current/JJ
proteomics/NNS
[/(
18/CD
]/)
./.
====================
Cost/NN
and/CC
time/NN
efficiency/NN
of/IN
these/DT
methods/NNS
also/RB
favoring/VBG
their/PRP$
preference/NN
over/IN
contemporary/JJ
in/IN
vitro/FW
techniques/NNS
[/(
19/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
have/VBP
used/VBN
several/JJ
well/RB
optimized/VBN
and/CC
up/IN
to/TO
date/NN
bioinformatics/NNS
tools/NNS
to/TO
assign/VB
functions/NNS
of/IN
a/DT
number/NN
of/IN
HPs/NNS
from/IN
the/DT
genome/NN
of/IN
S./NNP
flexneri/NN
with/IN
high/JJ
precision/NN
[/(
20/CD
]/)
./.
====================
Functional/JJ
domains/NNS
were/VBD
considered/VBN
as/IN
the/DT
basis/NN
to/TO
infer/VB
the/DT
biological/JJ
functions/NNS
of/IN
HPs/NNS
in/IN
this/DT
case/NN
./.
====================
The/DT
receiver/JJ
operating/VBG
characteristic/JJ
(/(
ROC/NN
)/)
analysis/NN
[/(
21/CD
]/)
was/VBD
used/VBN
for/IN
evaluating/VBG
the/DT
performance/NN
of/IN
bioinformatics/NNS
tools/NNS
executed/VBD
in/IN
our/PRP$
study/NN
./.
====================
We/PRP
also/RB
measured/VBD
the/DT
confidence/NN
level/NN
of/IN
the/DT
functional/JJ
predictions/NNS
on/IN
the/DT
basis/NN
of/IN
bioinformatics/NNS
tools/NNS
employed/VBN
during/IN
the/DT
course/NN
of/IN
the/DT
investigation/NN
[/(
22/CD
]/)
./.
====================
We/PRP
believe/VBP
that/IN
this/DT
analysis/NN
will/MD
expand/VB
our/PRP$
knowledge/NN
regarding/VBG
the/DT
functional/JJ
roles/NNS
of/IN
HPs/NNS
of/IN
Shigella/NN
and/CC
provide/VBP
an/DT
opportunity/NN
to/TO
unveil/VB
a/DT
number/NN
of/IN
potential/JJ
novel/JJ
drug/NN
targets/NNS
[/(
17/CD
]/)
./.
====================
The/DT
computational/JJ
algorithm/NN
used/VBN
for/IN
this/DT
study/NN
has/VBZ
been/VBN
illustrated/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
The/DT
entire/JJ
work/NN
scheme/VBP
has/VBZ
been/VBN
divided/VBN
into/IN
three/CD
phases/NNS
namely/RB
,/,
phase/NN
I/NN
,/,
II/CD
and/CC
III/CD
./.
====================
Phase/NN
I/NN
involves/VBZ
the/DT
characterization/NN
and/CC
sequence/NN
retrieval/NN
of/IN
the/DT
HPs/NNS
,/,
following/VBG
the/DT
analysis/NN
of/IN
the/DT
S./NNP
flexneri/NN
genome/NN
./.
====================
Phase/NN
II/CD
comprises/VBZ
of/IN
the/DT
annotation/NN
of/IN
various/JJ
functional/JJ
parameters/NNS
using/VBG
well/RB
optimized/VBN
series/NN
of/IN
tools/NNS
./.
====================
The/DT
probable/JJ
functions/NNS
of/IN
the/DT
characterized/VBN
HPs/NNS
were/VBD
predicted/VBN
by/IN
the/DT
integration/NN
of/IN
various/JJ
functional/JJ
predictions/NNS
./.
====================
In/IN
phase/NN
III/CD
,/,
an/DT
approach/NN
was/VBD
made/VBN
for/IN
systematic/JJ
performance/NN
evaluation/NN
of/IN
various/JJ
bioinformatics/NNS
tools/NNS
used/VBN
in/IN
this/DT
study/NN
./.
====================
In/IN
this/DT
case/NN
,/,
S./NNP
flexneri/NN
protein/NN
sequences/NNS
with/IN
known/VBN
function/NN
were/VBD
used/VBN
as/IN
control/JJ
./.
====================
Finally/RB
,/,
expert/VBP
knowledge/NN
was/VBD
applied/VBN
for/IN
annotation/NN
of/IN
HPs/NNS
at/IN
a/DT
considerable/JJ
degree/NN
of/IN
confidence/NN
./.
====================
Phase/NN
I/NN
====================
Accession/NN
of/IN
genome/NN
and/CC
sequence/NN
retrieval/NN
====================
Complete/JJ
genome/NN
sequence/NN
of/IN
S./FW
flexneri/NN
2a/NN
str/JJ
./.
====================
2457T/CD
was/VBD
retrieved/VBN
from/IN
NCBI/NN
database/NN
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/genome//JJ
)/)
and/CC
was/VBD
found/VBN
to/TO
code/VB
for/IN
a/DT
total/JJ
of/IN
4,362/CD
proteins/NNS
(/(
accessed/VBN
July/RB
5/CD
,/,
2017/CD
)/)
./.
====================
Fasta/NN
sequences/NNS
of/IN
the/DT
complete/JJ
coding/NN
sequence/NN
of/IN
682/CD
proteins/NNS
,/,
characterized/VBN
as/IN
HPs/NNS
were/VBD
retrieved/VBN
from/IN
UniProt/JJ
(/(
http/NN
:/:
//www.uniprot.org//JJ
)/)
./.
====================
Finally/RB
,/,
a/DT
total/JJ
of/IN
674/CD
proteins/NNS
were/VBD
retained/VBN
for/IN
downstream/JJ
analysis/NN
following/VBG
exclusion/NN
of/IN
duplicates/NNS
./.
====================
Analysis/NN
of/IN
the/DT
conserved/VBN
domains/NNS
====================
Domains/NNS
are/VBP
often/RB
identified/VBN
as/IN
recurring/VBG
(/(
sequence/NN
or/CC
structure/NN
)/)
units/VBZ
,/,
and/CC
can/MD
be/VB
thought/VBN
of/IN
as/IN
distinct/JJ
functional/JJ
and/or/CC
structural/JJ
units/NNS
of/IN
a/DT
protein/NN
./.
====================
During/IN
molecular/JJ
evolution/NN
,/,
it/PRP
is/VBZ
assumed/VBN
that/IN
domains/NNS
may/MD
have/VB
been/VBN
utilized/VBN
as/IN
building/VBG
blocks/VBZ
and/CC
have/VBP
encountered/VBN
recombination/NN
to/TO
modulate/VB
protein/NN
function/NN
[/(
23/CD
]/)
./.
====================
A/DT
domain/NN
or/CC
fold/JJ
might/MD
also/RB
exhibit/VBP
a/DT
higher/JJR
degree/NN
of/IN
conservancy/NN
when/WRB
compared/VBN
with/IN
the/DT
entire/JJ
sequence/NN
[/(
24/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
five/CD
bioinformatics/NNS
tools/NNS
namely/RB
:/:
CDD-BLAST/NN
(/(
Conserved/JJ
Domain/NN
Database-Basic/JJ
Local/JJ
Alignment/JJ
Search/JJ
Tool/NN
)/)
[/(
25–27/CD
]/)
,/,
PFAM/NN
[/(
28/CD
]/)
,/,
HmmScan/NNP
[/(
29/CD
]/)
,/,
SMART/NN
(/(
Simple/JJ
Modular/JJ
Architecture/NN
Research/NN
Tool/NN
)/)
[/(
30/CD
]/)
,/,
and/CC
SCANPROSITE/NN
[/(
31/CD
]/)
were/VBD
used/VBN
./.
====================
These/DT
tools/NNS
are/VBP
able/JJ
to/TO
search/VB
for/IN
the/DT
defined/VBN
conserved/VBN
domains/NNS
in/IN
the/DT
targeted/VBN
protein/NN
sequences/NNS
and/CC
further/RBR
assist/VBP
in/IN
the/DT
classification/NN
of/IN
putative/JJ
proteins/NNS
in/IN
a/DT
particular/JJ
protein/NN
family/NN
./.
====================
HPs/NNS
analyzed/VBD
by/IN
five/CD
aforementioned/VBN
function/NN
prediction/NN
web/NN
tools/NNS
revealed/VBD
the/DT
variable/JJ
results/NNS
when/WRB
searched/VBN
for/IN
the/DT
conserved/VBN
domains/NNS
in/IN
hypothetical/JJ
sequences/NNS
./.
====================
Therefore/RB
,/,
different/JJ
confidence/NN
levels/NNS
were/VBD
assigned/VBN
on/IN
the/DT
basis/NN
of/IN
collective/JJ
results/NNS
of/IN
these/DT
web-tools/NNS
./.
====================
One/CD
hundred/VBD
percentage/NN
confidence/NN
level/NN
was/VBD
considered/VBN
upon/IN
obtaining/VBG
the/DT
same/JJ
results/NNS
from/IN
the/DT
five/CD
distinct/JJ
tools/NNS
./.
====================
Finally/RB
,/,
we/PRP
obtained/VBD
39/CD
such/JJ
proteins/NNS
from/IN
674/CD
primary/JJ
collected/JJ
proteins/NNS
,/,
which/WDT
were/VBD
taken/VBN
for/IN
further/JJ
analysis/NN
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Phase/NN
II/CD
====================
Physicochemical/JJ
characterization/NN
====================
Theoretical/JJ
physiochemical/JJ
parameters/NNS
such/JJ
as/IN
molecular/JJ
weight/NN
,/,
isoelectric/JJ
point/NN
,/,
aliphatic/JJ
index/NN
,/,
instability/NN
index/NN
and/CC
grand/JJ
average/NN
of/IN
hydropathicity/NN
(/(
GRAVY/NN
)/)
of/IN
these/DT
HPs/NNS
were/VBD
analyzed/VBN
using/VBG
ProtParam/NN
server/RB
of/IN
the/DT
Expasy/NN
tools/NNS
(/(
http/NN
:/:
//web.expasy.org/protparam//JJ
)/)
./.
====================
Results/NNS
of/IN
this/DT
analysis/NN
have/VBP
been/VBN
listed/VBN
in/IN
Supplementary/JJ
Table/JJ
2/CD
./.
====================
Determination/NN
of/IN
sub-cellular/JJ
localization/NN
====================
For/IN
the/DT
identification/NN
of/IN
a/DT
protein/NN
as/IN
a/DT
drug/NN
or/CC
vaccine/NN
candidate/NN
,/,
determination/NN
of/IN
the/DT
sub-cellular/JJ
localization/NN
of/IN
the/DT
protein/NN
becomes/VBZ
particularly/RB
important/JJ
./.
====================
Surface/NN
membrane/NN
protein/NN
can/MD
be/VB
served/VBN
as/IN
a/DT
potential/JJ
vaccine/NN
target/NN
while/IN
cytoplasmic/JJ
proteins/NNS
may/MD
act/VB
as/IN
promising/JJ
drug/NN
targets/NNS
[/(
32/CD
]/)
./.
====================
We/PRP
used/VBD
CELLO/NN
[/(
33/CD
]/)
,/,
PSORTb/NN
[/(
34/CD
]/)
,/,
and/CC
PSLpred/JJ
[/(
35/CD
]/)
for/IN
the/DT
denotation/NN
of/IN
sub-cellular/JJ
localization/NN
of/IN
the/DT
query/NN
proteins/NNS
./.
====================
TMHMM/NN
,/,
SOSUI/NN
,/,
and/CC
HMMTOP/NN
were/VBD
applied/VBN
for/IN
the/DT
prediction/NN
of/IN
query/RB
proteins/NNS
for/IN
being/VBG
a/DT
membrane/NN
protein/NN
,/,
based/VBN
on/IN
Hidden/JJ
Markov/NNP
Model/NN
[/(
36–38/CD
]/)
./.
====================
SingnalP/NN
4.1/CD
[/(
39/CD
]/)
was/VBD
used/VBN
to/TO
predict/VB
the/DT
signal/NN
peptide/NN
and/CC
SecretomeP/NN
2.0/CD
[/(
40/CD
]/)
were/VBD
utilized/VBN
for/IN
the/DT
identification/NN
of/IN
proteins/NNS
involved/VBN
in/IN
non-classical/JJ
secretory/JJ
pathway/NN
./.
====================
Results/NNS
of/IN
these/DT
predictions/NNS
are/VBP
summarized/VBN
in/IN
Supplementary/JJ
Table/JJ
3/CD
./.
====================
Functional/JJ
prediction/NN
of/IN
the/DT
query/NN
proteins/NNS
====================
Various/JJ
tools/NNS
were/VBD
used/VBN
for/IN
precise/JJ
functional/JJ
assignments/NNS
of/IN
all/DT
39/CD
HPs/NNS
from/IN
S./NNP
flexneri/NN
(/(
described/VBN
in/IN
Table/JJ
1/CD
)/)
such/JJ
as/IN
CDD-Blast/JJ
,/,
Pfam/JJ
,/,
HmmScan/NNP
,/,
SMART/NN
,/,
Scanprosite/NN
,/,
MOTIF/NN
[/(
41/CD
]/)
,/,
INTERPROSCAN/NN
[/(
42/CD
]/)
,/,
CATH/NN
[/(
43/CD
]/)
,/,
SUPERFAMILY/NNP
[/(
44/CD
]/)
,/,
and/CC
Protonet/NN
[/(
45/CD
]/)
./.
====================
Results/NNS
of/IN
these/DT
analyses/NNS
have/VBP
been/VBN
outlined/VBN
in/IN
Supplementary/JJ
Tables/NNS
4/CD
and/CC
5/CD
./.
====================
The/DT
computational/JJ
prediction/NN
of/IN
the/DT
structure/NN
of/IN
a/DT
protein/NN
from/IN
its/PRP$
amino/NN
acid/NN
sequences/NNS
greatly/RB
facilitates/NNS
the/DT
subsequent/JJ
prediction/NN
of/IN
its/PRP$
function/NN
[/(
46/CD
]/)
./.
====================
An/DT
online/JJ
server/RB
PS2-v2/NN
(/(
PS/NN
Square/NN
version/NN
2/CD
)/)
[/(
47/CD
]/)
,/,
a/DT
template/JJ
based/VBN
method/NN
were/VBD
used/VBN
to/TO
predict/VB
the/DT
structure/NN
of/IN
the/DT
HPs/NNS
./.
====================
The/DT
modeling/JJ
of/IN
proteins/NNS
using/VBG
this/DT
online/JJ
server/RB
further/RBR
substantiated/VBD
the/DT
function/NN
of/IN
HPs/NNS
./.
====================
Besides/RB
,/,
PFP-FunDSeqE/NN
[/(
48/CD
]/)
has/VBZ
been/VBN
used/VBN
to/TO
elucidate/VB
the/DT
protein/NN
fold/JJ
patterns/NNS
based/VBN
on/IN
a/DT
combination/NN
of/IN
functional/JJ
domain/NN
information/NN
and/CC
evolutionary/JJ
information/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
Virulence/NN
factors/NNS
analysis/NN
====================
Virulence/RB
factors/NNS
(/(
VFs/NNS
)/)
are/VBP
described/VBN
as/IN
potent/JJ
targets/NNS
for/IN
developing/VBG
drugs/NNS
because/IN
it/PRP
is/VBZ
essential/JJ
for/IN
the/DT
severity/NN
of/IN
infection/NN
[/(
49/CD
]/)
./.
====================
VICMpred/JJ
[/(
50/CD
]/)
and/CC
Virulentpred/JJ
[/(
51/CD
]/)
tools/NNS
were/VBD
employed/VBN
to/TO
predict/VB
VFs/NNS
from/IN
protein/NN
sequences/NNS
with/IN
an/DT
accuracy/NN
of/IN
70.75/CD
%/NN
and/CC
81.8/CD
%/NN
,/,
respectively/RB
./.
====================
Functional/JJ
protein/NN
association/NN
networks/NNS
====================
The/DT
function/NN
and/CC
activity/NN
of/IN
a/DT
protein/NN
are/VBP
often/RB
modulated/VBN
by/IN
other/JJ
proteins/NNS
with/IN
which/WDT
it/PRP
interacts/VBZ
./.
====================
Therefore/RB
,/,
understanding/VBG
of/IN
protein-protein/JJ
interactions/NNS
serve/VBP
as/IN
valuable/JJ
leads/VBZ
for/IN
predicting/VBG
the/DT
function/NN
of/IN
a/DT
protein/NN
./.
====================
In/IN
this/DT
investigation/NN
,/,
we/PRP
had/VBD
employed/VBN
STRING/NN
(/(
Search/NN
Tool/NN
for/IN
the/DT
Retrieval/NN
of/IN
Interacting/JJ
Genes/Proteins/NNS
,/,
https/VBZ
:/:
//string-db.org//JJ
)/)
[/(
52/CD
]/)
to/TO
predict/VB
protein/NN
interactions/NNS
partners/NNS
of/IN
HPs/NNS
./.
====================
To/TO
predict/VB
functional/JJ
association/NN
,/,
only/RB
highest/JJS
confidence/NN
score/RB
partner/NN
proteins/NNS
were/VBD
chosen/NN
in/IN
this/DT
study/NN
./.
====================
Phase/NN
III/CD
====================
Performance/NN
assessment/NN
====================
The/DT
predicted/VBN
functions/NNS
of/IN
HPs/NNS
from/IN
S./NNP
flexneri/NN
and/CC
the/DT
accuracy/NN
of/IN
associated/VBN
tools/NNS
were/VBD
validated/VBN
using/VBG
the/DT
ROC/NN
curve/NN
analysis/NN
./.
====================
In/IN
this/DT
analysis/NN
,/,
the/DT
diagnostics/NNS
efficacy/NN
is/VBZ
evaluated/VBN
at/IN
six/CD
levels/NNS
where/WRB
1/CD
and/CC
0/CD
classified/VBN
as/IN
true/JJ
positive/JJ
and/CC
true/JJ
negative/JJ
respectively/RB
as/IN
binary/JJ
numerals/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
integers/NNS
(/(
2/CD
,/,
3/CD
,/,
4/CD
,/,
and/CC
5/CD
)/)
were/VBD
used/VBN
as/IN
confidence/NN
ratings/NNS
for/IN
each/DT
case/NN
./.
====================
The/DT
ROC/NN
curves/NNS
were/VBD
carried/VBN
out/RP
using/VBG
25/CD
S./NNP
flexneri/NN
proteins/NNS
with/IN
known/VBN
function/NN
as/IN
control/JJ
and/CC
were/VBD
compared/VBN
with/IN
the/DT
results/NNS
obtained/VBN
for/IN
the/DT
39/CD
HPs/NNS
(/(
Supplementary/JJ
Tables/NNS
6/CD
and/CC
7/CD
)/)
./.
====================
The/DT
results/NNS
were/VBD
submitted/VBN
to/TO
web-based/VBN
calculator/NN
for/IN
the/DT
ROC/NN
curves/NNS
[/(
53/CD
]/)
in/IN
“/NN
format/IN
1/CD
”/NN
form/VBP
and/CC
the/DT
program/NN
thereby/RB
calculated/VBN
the/DT
ROC/NN
curves/NNS
./.
====================
The/DT
results/NNS
were/VBD
expressed/VBN
in/IN
terms/NNS
of/IN
accuracy/NN
(/(
Ac/NNP
)/)
,/,
sensitivity/NN
(/(
Se/NN
)/)
,/,
specificity/NN
(/(
Sp/NN
)/)
and/CC
the/DT
area/NN
under/IN
the/DT
curve/JJ
(/(
AUC/NN
)/)
[/(
54/CD
]/)
./.
====================
The/DT
average/JJ
accuracy/NN
of/IN
the/DT
employed/VBN
pipeline/NN
was/VBD
found/VBN
93.6/CD
%/NN
(/(
Table/JJ
3/CD
,/,
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Sequence/NN
analysis/NN
====================
Sequences/NNS
of/IN
all/DT
the/DT
674/CD
HPs/NNS
were/VBD
analyzed/VBN
for/IN
identification/NN
of/IN
the/DT
functional/JJ
domains/NNS
using/VBG
five/CD
bioinformatics/NNS
tools/NNS
namely/RB
CDD-BLAST/NN
,/,
Pfam/JJ
,/,
HmmScan/JJ
,/,
SMART/NN
,/,
and/CC
SCANPROSITE/NN
./.
====================
If/IN
the/DT
given/VBN
five/CD
tools/NNS
indicated/VBD
the/DT
same/JJ
domains/NNS
for/IN
a/DT
protein/NN
,/,
we/PRP
considered/VBD
it/PRP
as/IN
100/CD
%/NN
confidence/NN
level/NN
./.
====================
In/IN
our/PRP$
study/NN
,/,
all/DT
the/DT
five/CD
tools/NNS
mentioned/JJ
above/JJ
revealed/VBD
39/CD
such/JJ
proteins/NNS
and/CC
hence/RB
were/VBD
grouped/VBN
together/RB
./.
====================
Only/RB
these/DT
HPs/NNS
having/VBG
100/CD
%/NN
confidence/NN
level/NN
were/VBD
considered/VBN
for/IN
further/JJ
analyses/NNS
and/CC
termed/VBN
as/IN
highly/RB
confident/JJ
(/(
Hconf/NNP
)/)
proteins/NNS
./.
====================
From/IN
the/DT
rest/NN
of/IN
the/DT
635/CD
proteins/NNS
,/,
no/DT
specific/JJ
conserved/VBN
domains/NNS
were/VBD
found/VBN
for/IN
a/DT
total/JJ
of/IN
257/CD
proteins/NNS
./.
====================
For/IN
other/JJ
HPs/NNS
(/(
n/NN
=/JJ
378/CD
)/)
,/,
specific/JJ
domains/NNS
were/VBD
identified/VBN
using/VBG
several/JJ
of/IN
these/DT
tools/NNS
./.
====================
To/TO
know/VB
accurate/VBP
function/NN
of/IN
these/DT
proteins/NNS
further/RBR
studies/NNS
are/VBP
required/VBN
./.
====================
The/DT
function/NN
of/IN
each/DT
of/IN
these/DT
39/CD
Hconf/NN
were/VBD
successfully/RB
assigned/VBN
by/IN
using/VBG
different/JJ
online/JJ
tools/NNS
,/,
listed/VBN
in/IN
Table/JJ
1/CD
./.
====================
All/DT
sequence/NN
analyses/NNS
were/VBD
compiled/VBN
and/CC
categorized/VBD
into/IN
various/JJ
functional/JJ
classes/NNS
constituting/VBG
9/CD
enzymes/NNS
,/,
10/CD
binding/VBG
proteins/NNS
,/,
4/CD
transporters/NNS
,/,
4/CD
lipoproteins/NNS
,/,
6/CD
which/WDT
are/VBP
involved/VBN
in/IN
various/JJ
cellular/JJ
processes/NNS
,/,
while/IN
6/CD
proteins/NNS
were/VBD
predicted/VBN
to/TO
exhibit/VB
miscellaneous/JJ
functions/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Various/JJ
functional/JJ
classes/NNS
of/IN
these/DT
classified/VBN
Hconf/NN
proteins/NNS
are/VBP
described/VBN
below/IN
./.
====================
Enzymes/NNS
====================
Enzymes/NNS
are/VBP
key/JJ
players/NNS
in/IN
many/JJ
leading/VBG
biochemical/JJ
processes/NNS
in/IN
the/DT
living/JJ
system/NN
and/CC
may/MD
facilitate/VB
the/DT
survival/NN
of/IN
pathogens/NNS
in/IN
the/DT
host/NN
and/CC
making/VBG
it/PRP
viable/JJ
for/IN
the/DT
course/NN
of/IN
infection/NN
./.
====================
A/DT
total/JJ
of/IN
9/CD
proteins/NNS
out/RP
of/IN
39/CD
(/(
23/CD
%/NN
)/)
of/IN
our/PRP$
annotated/JJ
Hconfs/NNS
were/VBD
characterized/VBN
as/IN
enzymes/NNS
./.
====================
Among/IN
these/DT
,/,
two/CD
proteins/NNS
were/VBD
characterized/VBN
as/IN
transferases/VBZ
,/,
among/IN
which/WDT
,/,
WP_000301054.1/NN
is/VBZ
a/DT
lipopolysaccharide/NN
kinase/NN
(/(
Kdo/WaaP/NN
)/)
,/,
involved/VBN
in/IN
the/DT
formation/NN
of/IN
outer/JJ
membrane/NN
(/(
OM/NN
)/)
of/IN
gram/NN
negative/JJ
bacteria/NNS
and/CC
is/VBZ
encoded/VBN
by/IN
the/DT
Waap/NN
gene/NN
./.
====================
The/DT
OM/NN
protects/VBZ
cells/NNS
from/IN
toxic/JJ
molecules/NNS
and/CC
is/VBZ
important/JJ
for/IN
survival/NN
during/IN
infection/NN
and/CC
is/VBZ
required/VBN
for/IN
virulence/NN
of/IN
the/DT
pathogen/NN
[/(
55/CD
]/)
./.
====================
According/VBG
to/TO
reports/NNS
made/VBD
by/IN
Delucia/NN
[/(
55/CD
]/)
,/,
the/DT
depletion/NN
of/IN
WaaP/NN
gene/NN
was/VBD
seen/VBN
to/TO
halt/VB
the/DT
growth/NN
of/IN
the/DT
bacteria/NNS
suggesting/VBG
that/IN
WaaP/NN
is/VBZ
essential/JJ
to/TO
produce/VB
the/DT
full-length/JJ
lipopolysaccharide/NN
,/,
recognized/VBD
by/IN
the/DT
OM/NN
[/(
49/CD
]/)
./.
====================
Therefore/RB
,/,
WaaP/NN
may/MD
result/VB
in/IN
a/DT
potent/JJ
target/NN
for/IN
the/DT
development/NN
of/IN
novel/JJ
antimicrobial/JJ
agents/NNS
./.
====================
The/DT
other/JJ
transferase/NN
,/,
protein/NN
WP_000778795.1/NN
was/VBD
found/VBN
to/TO
consist/VB
of/IN
an/DT
acetyltransferase/NN
(/(
GNAT/NN
)/)
domain/NN
that/DT
uses/VBZ
acetyl/NN
coenzyme/NN
A/NN
(/(
CoA/NN
)/)
to/TO
transfer/VB
an/DT
acetyl/NN
group/NN
to/TO
a/DT
substrate/JJ
,/,
a/DT
reaction/NN
implicated/VBD
in/IN
various/JJ
functions/NNS
for/IN
the/DT
development/NN
of/IN
antibiotic/JJ
resistance/NN
of/IN
bacteria/NNS
[/(
56/CD
]/)
./.
====================
Three/CD
enzymes/NNS
were/VBD
predicted/VBN
to/TO
be/VB
hydrolases/NNS
,/,
which/WDT
plays/VBZ
key/JJ
role/NN
in/IN
the/DT
invasion/NN
of/IN
the/DT
host/NN
tissue/NN
and/CC
evading/VBG
the/DT
host/NN
defense/NN
mechanism/NN
and/CC
are/VBP
thus/RB
associated/VBN
with/IN
various/JJ
VFs/NNS
[/(
57/CD
]/)
./.
====================
For/IN
instance/NN
,/,
WP_005051685.1/NN
marks/NNS
the/DT
lysin-like/JJ
motif/peptidase/NN
family/NN
M23/NN
,/,
is/VBZ
found/VBN
in/IN
proteins/NNS
from/IN
viruses/NNS
,/,
bacteria/NNS
,/,
fungi/VBP
,/,
plants/NNS
and/CC
mammals/NNS
./.
====================
It/PRP
is/VBZ
present/JJ
in/IN
bacterial/JJ
extracellular/JJ
proteins/NNS
including/VBG
hydrolases/NNS
,/,
adhesins/NNS
and/CC
VFs/NNS
such/JJ
as/IN
protein/NN
A/NN
from/IN
Staphylococcus/FW
aureus/FW
./.
====================
We/PRP
report/VBP
WP_001295493.1/NN
protein/NN
as/IN
the/DT
endoribonuclease/YjgF/JJ
family/NN
active/JJ
on/IN
single-stranded/JJ
mRNA/NN
that/WDT
inhibits/VBZ
protein/NN
synthesis/NN
by/IN
cleaving/VBG
mRNA/NN
[/(
58/CD
]/)
./.
====================
YjgF/NN
family/NN
members/NNS
are/VBP
enamine/imine/VBP
deaminases/NNS
that/DT
hydrolyze/VBP
reactive/JJ
intermediates/NNS
released/VBN
by/IN
pyridoxal/JJ
phosphate-dependent/JJ
enzymes/NNS
,/,
including/VBG
threonine/NN
dehydratase/NN
[/(
59/CD
]/)
./.
====================
It/PRP
has/VBZ
also/RB
been/VBN
reported/VBN
in/IN
the/DT
inhibition/NN
of/IN
transaminase/NN
B/NN
in/IN
Salmonella/NN
[/(
60/CD
]/)
./.
====================
Among/IN
the/DT
other/JJ
enzymes/NNS
predicted/VBN
,/,
there/EX
has/VBZ
been/VBN
two/CD
isomerase/NN
and/CC
one/CD
lyase/NN
enzyme/NN
./.
====================
WP_001247854.1/NN
constitutes/VBZ
the/DT
toprim/NN
(/(
topoisomerase-primase/NN
)/)
,/,
a/DT
catalytic/JJ
domain/NN
involved/VBN
in/IN
breakage/NN
and/CC
rejoining/VBG
of/IN
DNA/NN
strand/NN
[/(
61/CD
]/)
./.
====================
WP_001205243.1/NN
marks/NNS
the/DT
Xylose/NN
isomerase-like/JJ
TIM/NN
barrel/NN
involved/VBN
in/IN
the/DT
myo-inositol/NN
catabolism/NN
pathway/NN
[/(
62/CD
]/)
./.
====================
Lyases/NNS
also/RB
play/VBP
a/DT
key/JJ
role/NN
in/IN
bacterial/JJ
pathogenesis/NN
due/JJ
to/TO
their/PRP$
involvements/NNS
in/IN
various/JJ
biosynthesis/NN
processes/NNS
./.
====================
WP_000943980.1/NN
was/VBD
found/VBN
to/TO
demonstrate/VB
synthase/NN
activity/NN
that/WDT
causes/VBZ
hydrolysis/NN
of/IN
ATP/NN
with/IN
the/DT
formation/NN
of/IN
an/DT
amide/NN
bond/NN
between/IN
spermidine/NN
and/CC
the/DT
glycine/NN
carboxylate/JJ
of/IN
glutathione/NN
./.
====================
In/IN
the/DT
pathogenic/JJ
trypanosomatids/NNS
,/,
this/DT
reaction/NN
is/VBZ
the/DT
penultimate/NN
step/NN
in/IN
the/DT
biosynthesis/NN
of/IN
the/DT
antioxidant/JJ
metabolite/NN
,/,
and/CC
is/VBZ
a/DT
resounding/VBG
target/NN
for/IN
target/NN
mediated/VBN
drug/NN
design/NN
[/(
63/CD
]/)
./.
====================
The/DT
WP_000454701.1/NN
protein/NN
was/VBD
found/VBN
to/TO
be/VB
a/DT
cystathionine/JJ
b-lyase/NN
,/,
an/DT
enzyme/NN
which/WDT
forms/VBZ
the/DT
cystathionine/NN
intermediate/JJ
in/IN
cysteine/NN
biosynthesis/NN
and/CC
may/MD
be/VB
considered/VBN
as/IN
the/DT
target/NN
for/IN
pyridiamine/NN
anti-microbial/JJ
agents/NNS
[/(
64/CD
]/)
./.
====================
Binding/NN
proteins/NNS
====================
Ten/CD
proteins/NNS
annotated/VBN
as/IN
binding/VBG
proteins/NNS
among/IN
which/WDT
1/CD
RNA/NN
binding/NN
,/,
3/CD
protein/NN
binding/NN
,/,
3/CD
lipid/NN
binding/NN
,/,
1/CD
metal/JJ
binding/NN
,/,
1/CD
peptidoglycan/NN
binding/VBG
,/,
and/CC
1/CD
adhesion/NN
protein/NN
have/VBP
been/VBN
predicted/VBN
./.
====================
WP_000132640.1/NN
protein/NN
was/VBD
predicted/VBN
to/TO
be/VB
SymE/JJ
(/(
SOS-induced/JJ
yjiW/NN
gene/NN
with/IN
similarity/NN
to/TO
MazE/JJ
)/)
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
to/TO
involve/VB
in/IN
inhibiting/VBG
cell/NN
growth/NN
,/,
decrease/NN
protein/NN
synthesis/NN
and/CC
increase/VBP
RNA/NN
degradation/NN
and/CC
thus/RB
exhibit/VBP
a/DT
vital/JJ
role/NN
in/IN
the/DT
survival/NN
and/CC
propagation/NN
of/IN
pathogen/NN
in/IN
the/DT
host/NN
[/(
65/CD
,/,
66/CD
]/)
./.
====================
Despite/IN
not/RB
manifesting/VBG
any/DT
functional/JJ
homology/NN
with/IN
other/JJ
type/NN
I/CD
toxin/NN
proteins/NNS
,/,
SymE/NN
belongs/VBZ
to/TO
the/DT
type/NN
I/CD
toxin-antitoxin/NN
system/NN
./.
====================
Its/PRP$
function/NN
resembles/VBZ
that/DT
of/IN
type/NN
II/CD
toxins/NNS
such/JJ
as/IN
MazF/JJ
,/,
which/WDT
is/VBZ
able/JJ
to/TO
perform/VB
the/DT
cleavage/NN
of/IN
mRNA/NN
in/IN
a/DT
ribosome/NN
independent/JJ
manner/NN
./.
====================
However/RB
,/,
SymE/NN
shares/VBZ
homology/NN
to/TO
the/DT
AbrB-fold/JJ
superfamily/NN
proteins/NNS
such/JJ
as/IN
MazE/JJ
,/,
which/WDT
acts/VBZ
as/IN
transcriptional/JJ
factors/NNS
and/CC
antitoxins/NNS
in/IN
various/JJ
type/NN
II/CD
TA/NN
modules/NNS
[/(
67/CD
]/)
./.
====================
It/PRP
seems/VBZ
probable/JJ
that/DT
SymE/JJ
has/VBZ
evolved/VBN
into/IN
an/DT
RNA/NN
cleavage/NN
protein/NN
with/IN
toxin-like/JJ
properties/NNS
from/IN
a/DT
transcription/NN
factor/NN
or/CC
antitoxin/JJ
[/(
66/CD
]/)
./.
====================
In/IN
our/PRP$
study/NN
,/,
we/PRP
reported/VBD
WP_000003197.1/NN
as/IN
von/NN
Willebrand/NN
factor/NN
with/IN
a/DT
type/NN
A/NN
domain/NN
which/WDT
has/VBZ
been/VBN
reported/VBN
responsible/JJ
for/IN
various/JJ
blood/NN
disorders/NNS
[/(
68–70/CD
]/)
./.
====================
The/DT
association/NN
of/IN
type/NN
A/NN
domain/NN
makes/VBZ
it/PRP
liable/JJ
to/TO
be/VB
involved/VBN
in/IN
various/JJ
significant/JJ
activities/NNS
such/JJ
as/IN
cell/NN
adhesion/NN
and/CC
immune/JJ
defense/NN
[/(
71/CD
]/)
./.
====================
On/IN
the/DT
other/JJ
hand/NN
,/,
WP_000755956.1/NN
has/VBZ
been/VBN
predicted/VBN
to/TO
belong/VB
to/TO
the/DT
band-7/NN
protein/NN
family/NN
that/WDT
comprises/VBZ
of/IN
a/DT
diverse/JJ
set/NN
of/IN
membrane-bound/JJ
proteins/NNS
characterized/VBN
by/IN
the/DT
presence/NN
of/IN
a/DT
conserved/VBN
domain/NN
[/(
72/CD
]/)
./.
====================
The/DT
exact/JJ
function/NN
of/IN
this/DT
domain/NN
is/VBZ
not/RB
known/VBN
,/,
but/CC
concurrent/JJ
reports/NNS
from/IN
animal/NN
and/CC
bacterial/JJ
stomatin-type/NN
proteins/NNS
demonstrate/VBP
the/DT
ability/NN
of/IN
binding/VBG
to/TO
lipids/NNS
and/CC
in/IN
the/DT
assembly/NN
of/IN
membrane-bound/JJ
oligomers/NNS
that/IN
form/VBP
putative/JJ
scaffolds/VBZ
[/(
73/CD
]/)
./.
====================
We/PRP
have/VBP
also/RB
predicted/VBN
WP_001269672.1/NN
and/CC
WP_000749269.1/NN
as/IN
the/DT
lipid/NN
binding/NN
domain/NN
called/VBN
lipopolysaccharide/NN
(/(
LPS/NN
)/)
-assembly/RB
lipoprotein/NN
LptE/NN
and/CC
the/DT
YceI-like/JJ
domain/NN
respectively/RB
./.
====================
The/DT
LPS/NN
transport/VBP
machinery/NN
is/VBZ
composed/VBN
of/IN
LptA/JJ
,/,
LptB/NN
,/,
LptC/NN
,/,
LptD/NN
,/,
and/CC
LptE/JJ
./.
====================
LptE/JJ
forms/NNS
a/DT
complex/NN
with/IN
LptD/JJ
,/,
which/WDT
is/VBZ
involved/VBN
in/IN
the/DT
assembly/NN
of/IN
LPS/NN
in/IN
the/DT
outer/NN
leaflet/NN
of/IN
the/DT
OM/NN
[/(
74/CD
]/)
./.
====================
This/DT
OM/NN
is/VBZ
an/DT
effective/JJ
permeability/NN
barrier/RBR
that/DT
protects/VBZ
the/DT
cells/NNS
from/IN
toxic/JJ
compounds/NNS
,/,
such/JJ
as/IN
antibiotics/NNS
and/CC
detergents/NNS
,/,
thus/RB
conferring/VBG
the/DT
bacteria/NNS
with/IN
the/DT
capability/NN
to/TO
adapt/VB
and/CC
consequently/RB
inhabit/VBP
several/JJ
different/JJ
and/CC
often/RB
hostile/NN
environments/NNS
./.
====================
Among/IN
the/DT
binding/NN
prtoteins/NNS
,/,
WP_000266171.1/NN
was/VBD
found/VBN
to/TO
be/VB
a/DT
tetratricopeptide/JJ
repeat/NN
containing/VBG
protein/NN
which/WDT
is/VBZ
involved/VBN
in/IN
protein-protein/JJ
interactions/NNS
and/CC
thus/RB
plays/VBZ
an/DT
important/JJ
role/NN
in/IN
virulence/NN
[/(
75/CD
]/)
./.
====================
Cellular/JJ
processes/regulatory/JJ
proteins/NNS
====================
A/DT
total/JJ
of/IN
6/CD
HPs/NNS
have/VBP
been/VBN
predicted/VBN
to/TO
be/VB
involved/VBN
in/IN
various/JJ
cellular/JJ
and/CC
regulatory/JJ
mechanisms/NNS
,/,
which/WDT
are/VBP
vital/JJ
cognates/NNS
in/IN
the/DT
pathogenesis/NN
of/IN
S./NNP
flexneri/NN
and/CC
thus/RB
can/MD
be/VB
treated/VBN
as/IN
possible/JJ
drug/NN
targets/NNS
[/(
76/CD
]/)
./.
====================
For/IN
example/NN
,/,
WP_000189314.1/NN
predicted/VBN
to/TO
be/VB
a/DT
member/NN
of/IN
the/DT
GIY-YIG/NN
family/NN
involved/VBN
in/IN
many/JJ
cellular/JJ
processes/NNS
including/VBG
DNA/NN
repair/NN
and/CC
recombination/NN
,/,
transfer/NN
of/IN
mobile/JJ
genetic/JJ
elements/NNS
,/,
and/CC
restriction/NN
of/IN
incoming/VBG
foreign/JJ
DNA/NN
[/(
77/CD
,/,
78/CD
]/)
./.
====================
WP_001387238.1/NN
and/CC
WP_001297375.1/NN
have/VBP
been/VBN
found/VBN
to/TO
be/VB
RadC-like/JJ
domain/NN
belonging/VBG
to/TO
the/DT
JAB/NN
superfamily/NN
of/IN
metalloproteins/NNS
[/(
79/CD
]/)
./.
====================
In/IN
most/JJS
instances/NNS
,/,
this/DT
domain/NN
shows/VBZ
fusions/NNS
to/TO
an/DT
N-terminal/JJ
Helix-hairpin-Helix/JJ
(/(
HhH/NN
)/)
domain/NN
and/CC
may/MD
also/RB
be/VB
function/NN
as/IN
a/DT
nuclease/NN
[/(
79/CD
]/)
./.
====================
WP_000848528.1/NN
has/VBZ
been/VBN
predicted/VBN
to/TO
be/VB
a/DT
leucine-zipper/NN
found/VBN
in/IN
the/DT
enterobacterial/JJ
OM/NN
lipoprotein/NN
LPP/NN
[/(
80/CD
]/)
./.
====================
It/PRP
is/VBZ
likely/JJ
that/IN
this/DT
domain/NN
is/VBZ
involved/VBN
in/IN
protein-protein/JJ
interaction/NN
via/IN
subsequent/JJ
oligomerization/NN
./.
====================
WP_000597196.1/CD
and/CC
WP_048814497.1/NN
have/VBP
been/VBN
respectively/RB
found/VBN
to/TO
be/VB
a/DT
Glycine/NN
zipper/NN
2TM/NN
domain/NN
found/VBN
in/IN
the/DT
Rickettsia/NN
genus/NN
and/CC
leucine-rich/JJ
repeat/NN
involved/VBN
in/IN
a/DT
variety/NN
of/IN
biological/JJ
processes/NNS
,/,
including/VBG
signal/NN
transduction/NN
,/,
cell/NN
adhesion/NN
,/,
DNA/NN
repair/NN
,/,
recombination/NN
,/,
transcription/NN
,/,
RNA/NN
processing/NN
,/,
disease/NN
resistance/NN
,/,
apoptosis/NN
,/,
and/CC
the/DT
immune/JJ
response/NN
[/(
81/CD
]/)
./.
====================
Lipoprotein/NN
====================
Bacterial/JJ
lipoproteins/NNS
are/VBP
a/DT
set/NN
of/IN
membrane/NN
proteins/NNS
with/IN
many/JJ
different/JJ
functions/NNS
./.
====================
Due/IN
to/TO
this/DT
broad-ranging/VBG
functionality/NN
,/,
these/DT
proteins/NNS
have/VBP
a/DT
considerable/JJ
significance/NN
in/IN
many/JJ
phenomena/NNS
,/,
from/IN
cellular/JJ
physiology/NN
through/IN
cell/NN
division/NN
and/CC
virulence/NN
[/(
82/CD
]/)
./.
====================
Lipoprotein/NN
of/IN
gram-negative/JJ
bacteria/NNS
is/VBZ
essential/JJ
for/IN
growth/NN
and/CC
division/NN
[/(
83/CD
]/)
./.
====================
In/IN
our/PRP$
analysis/NN
,/,
we/PRP
report/VBP
a/DT
total/JJ
of/IN
4/CD
lipoproteins/NNS
from/IN
the/DT
group/NN
of/IN
HPs/NNS
predicted/VBN
in/IN
this/DT
study/NN
./.
====================
It/PRP
has/VBZ
been/VBN
also/RB
revealed/VBD
that/IN
lipoproteins/NNS
may/MD
function/VB
as/IN
vaccines/NNS
[/(
82/CD
]/)
./.
====================
The/DT
knowledge/NN
of/IN
these/DT
facts/NNS
may/MD
be/VB
utilized/VBN
for/IN
the/DT
generation/NN
of/IN
novel/JJ
countermeasures/NNS
to/TO
bacterial/JJ
diseases/NNS
[/(
82/CD
]/)
./.
====================
Transport/JJ
====================
In/IN
our/PRP$
findings/NNS
,/,
we/PRP
report/VBP
the/DT
prediction/NN
of/IN
HP/NN
WP_000070107.1/NN
to/TO
be/VB
a/DT
member/NN
of/IN
the/DT
ATP-binding/JJ
cassette/JJ
superfamily/NN
,/,
largest/JJS
of/IN
all/DT
protein/NN
families/NNS
with/IN
a/DT
diversity/NN
of/IN
physiological/JJ
functions/NNS
[/(
84/CD
]/)
./.
====================
It/PRP
has/VBZ
recently/RB
been/VBN
identified/VBN
that/WDT
these/DT
proteins/NNS
may/MD
be/VB
involved/VBN
in/IN
virulence/NN
and/CC
are/VBP
essential/JJ
for/IN
intracellular/JJ
survival/NN
of/IN
pathogens/NNS
[/(
85/CD
]/)
./.
====================
We/PRP
have/VBP
found/VBN
protein/NN
WP_001296791.1/NN
to/TO
be/VB
an/DT
auto-transporter/NN
of/IN
the/DT
YhjY/NN
type/NN
involved/VBN
in/IN
DNA/NN
repair/NN
[/(
86/CD
]/)
./.
====================
Protein/NN
WP_001238362.1/NN
has/VBZ
been/VBN
found/VBN
to/TO
exhibit/VB
the/DT
function/NN
of/IN
transport/NN
of/IN
nutrients/NNS
,/,
control/NN
of/IN
cell/NN
regulation/NN
,/,
pheromone/NN
transport/VBP
,/,
cryptic/JJ
coloration/NN
and/CC
in/IN
the/DT
enzymatic/JJ
synthesis/NN
of/IN
prostaglandins/NNS
./.
====================
An/DT
example/NN
a/DT
protein/NN
with/IN
such/JJ
function/NN
is/VBZ
the/DT
retinol-binding/VBG
protein/NN
4/CD
,/,
which/WDT
transfers/VBZ
retinol/NN
from/IN
liver/NN
to/TO
peripheral/JJ
tissues/NNS
[/(
87/CD
]/)
./.
====================
Other/JJ
proteins/NNS
====================
Six/CD
HPs/NNS
have/VBP
been/VBN
predicted/VBN
to/TO
exhibit/VB
miscellaneous/JJ
functions/NNS
where/WRB
most/JJS
of/IN
them/PRP
are/VBP
protein/NN
with/IN
unknown/JJ
function/NN
./.
====================
Among/IN
them/PRP
,/,
WP_001382892.1/NN
and/CC
WP_000691930.1/NN
have/VBP
been/VBN
preicted/VBN
to/TO
be/VB
domains/NNS
of/IN
unknown/JJ
function/NN
and/CC
are/VBP
found/VBN
in/IN
a/DT
number/NN
of/IN
bacterial/JJ
proteins/NNS
./.
====================
WP_001125713.1/NN
has/VBZ
been/VBN
found/VBN
to/TO
be/VB
YcgL/NN
domain/NN
with/IN
conserved/VBN
class/NN
of/IN
small/JJ
proteins/NNS
widespread/JJ
in/IN
gammaproteo/JJ
bacteria/NNS
./.
====================
This/DT
group/NN
of/IN
proteins/NNS
contain/VBP
a/DT
85-residue/JJ
domain/NN
of/IN
unknown/JJ
function/NN
and/CC
two/CD
alpha-helices/NNS
and/CC
four/CD
beta-strands/NNS
in/IN
the/DT
sequential/JJ
arrangement/NN
[/(
88/CD
]/)
./.
====================
We/PRP
have/VBP
also/RB
predicted/VBN
WP_001237866.1/NN
and/CC
WP_005049020.1/NN
as/IN
YecR/NN
and/CC
YehR/NN
like/IN
family/NN
of/IN
lipoproteins/NNS
found/VBD
in/IN
bacteria/NNS
and/CC
viruses/NNS
and/CC
are/VBP
functionally/RB
uncharacterized/JJ
./.
====================
Virulent/JJ
proteins/NNS
====================
Gram-negative/JJ
bacteria/NNS
undergo/VBP
frequent/JJ
genomic/JJ
alterations/NNS
and/CC
consequent/JJ
evolutions/NNS
thus/RB
increasing/VBG
their/PRP$
virulence/NN
inside/NN
the/DT
host/NN
environment/NN
[/(
89/CD
]/)
./.
====================
We/PRP
have/VBP
found/VBN
2/CD
HPs/NNS
that/DT
showed/VBD
positive/JJ
virulence/NN
scores/VBZ
servers/NNS
among/IN
the/DT
Hconf/NN
proteins/NNS
./.
====================
These/DT
have/VBP
been/VBN
listed/VBN
in/IN
Supplementary/JJ
Table/JJ
8/CD
./.
====================
It/PRP
had/VBD
already/RB
been/VBN
hypothesized/VBN
that/IN
targeting/VBG
VF/NN
provides/VBZ
a/DT
better/RBR
therapeutic/JJ
intervention/NN
strategy/NN
against/IN
bacterial/JJ
pathogenesis/NN
[/(
89/CD
]/)
./.
====================
Predicted/VBN
HPs/NNS
having/VBG
virulent/JJ
characteristics/NNS
thus/RB
provide/VBP
powerful/JJ
target-based/VBN
therapies/NNS
for/IN
the/DT
mitigation/NN
of/IN
an/DT
existing/VBG
infection/NN
and/CC
are/VBP
further/RBR
considered/VBN
as/IN
an/DT
adjunct/JJ
therapy/NN
to/TO
existing/VBG
antibiotics/NNS
,/,
or/CC
potentiators/NNS
of/IN
the/DT
host/NN
immune/JJ
response/NN
[/(
90/CD
]/)
./.
====================
ROC/NN
curve/NN
====================
The/DT
average/JJ
accuracy/NN
of/IN
the/DT
employed/VBN
pipeline/NN
was/VBD
identified/VBN
93.6/CD
%/NN
in/IN
our/PRP$
analysis/NN
which/WDT
indicated/VBD
that/IN
outcomes/VBZ
of/IN
the/DT
functional/JJ
annotation/NN
of/IN
HPs/NNS
were/VBD
predicted/VBN
with/IN
a/DT
high/JJ
degree/NN
of/IN
confidence/NN
./.
====================
We/PRP
have/VBP
also/RB
found/VBD
sensitivity/NN
of/IN
100/CD
%/NN
and/CC
specificity/NN
64.3/CD
%/NN
for/IN
the/DT
tools/NNS
used/VBN
in/IN
this/DT
study/NN
./.
====================
Finally/RB
,/,
area/NN
under/IN
the/DT
curve/NN
was/VBD
found/VBN
to/TO
be/VB
0.774/CD
./.
====================
AUC/NN
is/VBZ
an/DT
effective/JJ
way/NN
to/TO
summarize/VB
the/DT
overall/JJ
diagnostic/JJ
accuracy/NN
of/IN
the/DT
test/NN
./.
====================
It/PRP
takes/VBZ
values/NNS
from/IN
0/CD
to/TO
1/CD
,/,
where/WRB
0.7/CD
to/TO
0.8/CD
is/VBZ
considered/VBN
acceptable/JJ
./.
====================
Conclusion/NN
====================
Using/VBG
an/DT
innovative/JJ
in/IN
silico/JJ
approach/NN
,/,
all/DT
674/CD
HPs/NNS
from/IN
S./NNP
flexneri/NN
were/VBD
primarily/RB
analyzed/VBD
and/CC
then/RB
using/VBG
the/DT
ROC/NN
analysis/NN
and/CC
confidence/NN
level/NN
measurements/NNS
of/IN
the/DT
predicted/VBN
results/NNS
the/DT
functions/NNS
of/IN
the/DT
39/CD
HPs/NNS
were/VBD
precisely/RB
predicted/VBN
with/IN
a/DT
reasonably/RB
high/JJ
degree/NN
of/IN
confidence/NN
and/CC
thereby/RB
were/VBD
successfully/RB
characterized/VBN
./.
====================
Following/VBG
this/DT
,/,
the/DT
validation/NN
of/IN
the/DT
functions/NNS
of/IN
these/DT
proteins/NNS
were/VBD
carried/VBN
out/RP
by/IN
using/VBG
different/JJ
approaches/NNS
including/VBG
structure/NN
based/VBN
PS2-v2/NN
server/RB
,/,
sub-cellular/JJ
localization/NN
and/CC
physicochemical/JJ
parameters/NNS
./.
====================
These/DT
are/VBP
important/JJ
for/IN
distinguishing/VBG
the/DT
HPs/NNS
from/IN
the/DT
rest/NN
of/IN
the/DT
protein/NN
./.
====================
The/DT
protein-protein/JJ
interaction/NN
also/RB
gave/VBD
insights/NNS
in/IN
elucidation/NN
of/IN
the/DT
involvement/NN
of/IN
such/JJ
proteins/NNS
in/IN
various/JJ
metabolic/JJ
pathways/NNS
./.
====================
Moreover/RB
,/,
some/DT
virulence/NN
proteins/NNS
had/VBD
also/RB
been/VBN
detected/VBN
which/WDT
are/VBP
essential/JJ
for/IN
the/DT
survival/NN
of/IN
this/DT
pathogen/NN
./.
====================
This/DT
in/IN
silico/NN
approach/NN
for/IN
functional/JJ
annotation/NN
of/IN
the/DT
HPs/NNS
can/MD
be/VB
further/RBR
utilized/VBD
in/IN
drug/NN
discovery/NN
for/IN
characterizing/VBG
putative/JJ
drug/NN
targets/NNS
for/IN
other/JJ
clinically/RB
important/JJ
pathogens/NNS
./.
====================
The/DT
outcomes/NNS
of/IN
ROC/NN
analysis/NN
indicated/VBD
high/JJ
reliability/NN
of/IN
bioinformatics/NNS
tools/NNS
used/VBN
in/IN
this/DT
study/NN
./.
====================
Hence/RB
,/,
the/DT
functional/JJ
annotation/NN
of/IN
HPs/NNS
is/VBZ
reliable/JJ
and/CC
can/MD
be/VB
further/RBR
utilized/VBD
for/IN
other/JJ
experimental/JJ
research/NN
./.
====================
Computational/JJ
algorithm/NN
used/VBN
for/IN
annotating/VBG
function/NN
of/IN
39/CD
hypothetical/JJ
proteins/NNS
(/(
HPs/NNS
)/)
from/IN
Shigella/NN
flexneri/NN
./.
====================
The/DT
framework/NN
has/VBZ
been/VBN
divided/VBN
into/IN
three/CD
phases/NNS
:/:
PHASE/NN
I/NN
,/,
sequence/NN
retrieval/JJ
from/IN
online/JJ
databases/NNS
;/:
PHASE/NN
II/CD
,/,
the/DT
extensive/JJ
analysis/NN
of/IN
sub-cellular/JJ
localization/NN
,/,
physicochemical/JJ
parameters/NNS
,/,
virulence/RB
,/,
function/NN
and/CC
domain/NN
present/JJ
in/IN
HPs/NNS
;/:
PHASE/NN
III/CD
,/,
assessment/JJ
of/IN
the/DT
predicted/VBN
functions/NNS
using/VBG
the/DT
protein/NN
with/IN
known/VBN
function/NN
from/IN
S./NNP
flexneri/FW
and/CC
reliable/JJ
prediction/NN
of/IN
possible/JJ
functions/NNS
of/IN
HPs/NNS
./.
====================
Receiver/RB
operating/VBG
characteristic/JJ
(/(
ROC/NN
)/)
curve/VBP
(/(
area/NN
under/IN
the/DT
curve/JJ
[/(
AUC/NN
]/)
=/JJ
0.774/CD
)/)
for/IN
average/JJ
accuracy/NN
of/IN
prediction/NN
./.
====================
Hypothetical/JJ
proteins/NNS
classified/VBN
into/IN
different/JJ
groups/NNS
based/VBN
on/IN
their/PRP$
functions/NNS
./.
====================
List/NN
of/IN
annotated/JJ
Hconf/NN
proteins/NNS
from/IN
Shigella/NN
flexneri/NN
====================
Different/JJ
types/NNS
of/IN
folds/NNS
identified/VBN
in/IN
Shigella/NN
flexneri/NN
====================
List/NN
of/IN
accuracy/NN
,/,
sensitivity/NN
,/,
specificity/NN
,/,
and/CC
ROC/NN
area/NN
of/IN
various/JJ
bioinformatics/NNS
tools/NNS
used/VBN
for/IN
predicting/VBG
function/NN
of/IN
Hconf/JJ
proteins/NNS
from/IN
Shigella/NN
flexneri/NN
obtained/VBN
after/IN
ROC/NN
analysis/NN
====================
